GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors

Trial status:Recruiting
Study Identifier:
GCT1042-01
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
Genmab
Recruiting

Trial details

Medical Condition
  • Solid Tumors
  • Lung Cancer
  • Colorectal Cancer
  • Skin Cancer
  • Head and Neck Cancer
  • Pancreatic Cancer
  • Study Drug
  • Biological: GEN1042
  • Drug: Pembrolizumab
  • Drug: Cisplatin
  • See more
  • Drug: Carboplatin
  • Drug: 5-FU
  • Drug: Gemcitabine
  • Drug: Nab paclitaxel
  • Drug: Pemetrexed
  • Drug: Paclitaxel
  • Phase
    Phase 1
    Sex
    Female & Male
    Age
    18+
    Estimated Trial Date
    Sep 2019 - Jul 2025

    Protocol summary

    To evaluate the safety and anti-tumor activity of GEN1042 in patients with metastatic or locally advanced solid tumors.

    Trial locations

    Location
    Status
    Location
    Alaska Oncology and Hematology LLC
    Anchorage, Alaska, United States, 99508
    Status
    Recruiting
    Location
    Cancer & Blood Specialty Clinic
    Los Alamitos, California, United States, 90720
    Status
    Recruiting
    Location
    Moores Cancer Center at the UC San Diego Health
    San Diego, California, United States, 92037
    Status
    Recruiting
    Location
    Yale University Cancer Center
    New Haven, Connecticut, United States, 06520
    Status
    Recruiting
    Location
    ChristianaCare
    Newark, Delaware, United States, 19713
    Status
    Recruiting
    Location
    Mount Sinai Comprehensive Cancer Center
    Miami Beach, Florida, United States, 33140
    Status
    Recruiting